These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
73 related articles for article (PubMed ID: 10452316)
1. Role of FDG PET in metastatic thyroid cancer. Wong CO; Dworkin HJ J Nucl Med; 1999 Jun; 40(6):993-4. PubMed ID: 10452316 [No Abstract] [Full Text] [Related]
2. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315 [TBL] [Abstract][Full Text] [Related]
3. Extensive lymph node metastases found by (18)F-FDG-PET/CT in a patient with diffuse sclerosing variant of papillary thyroid carcinoma. Xu YH; Song HJ; Qiu ZL; Luo QY Hell J Nucl Med; 2011; 14(2):188-9. PubMed ID: 21761030 [No Abstract] [Full Text] [Related]
4. 18F-FDG SPECT/CT in the diagnosis of differentiated thyroid carcinoma with elevated thyroglobulin and negative iodine-131 scans. Ma C; Wang X; Shao M; Zhao L; Jiawei X; Wu Z; Wang H Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):220-7. PubMed ID: 24844253 [TBL] [Abstract][Full Text] [Related]
5. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792 [TBL] [Abstract][Full Text] [Related]
6. [PET-FDG in thyroid cancer with high thyroglobulin levels and negative 131-I scan. A case report]. Ortega F; Maldonado A; Marañes P; Montz R; Pérez-Castejón MJ; Melgarejo M; Ruiz JA; Carreras JL Rev Esp Med Nucl; 1999; 18(1):50-4. PubMed ID: 10074219 [TBL] [Abstract][Full Text] [Related]
7. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. Laking GR; Price PM J Nucl Med; 2002 Dec; 43(12):1728-9; author reply 1729. PubMed ID: 12468527 [No Abstract] [Full Text] [Related]
8. Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin. Kim SJ; Lee TH; Kim IJ; Kim YK Eur J Radiol; 2009 Apr; 70(1):17-24. PubMed ID: 18207685 [TBL] [Abstract][Full Text] [Related]
9. FDG PET and alternative imaging in the management of thyroid carcinoma. Al-Nahhas AM Nucl Med Rev Cent East Eur; 2003; 6(2):139-45. PubMed ID: 14737730 [TBL] [Abstract][Full Text] [Related]
10. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Wang W; Larson SM; Tuttle RM; Kalaigian H; Kolbert K; Sonenberg M; Robbins RJ Thyroid; 2001 Dec; 11(12):1169-75. PubMed ID: 12186505 [TBL] [Abstract][Full Text] [Related]
11. Follow-up in patients with differentiated thyroid carcinoma with positive 18F-fluoro-2-deoxy-D-glucose-positron emission tomography results, elevated thyroglobulin levels, and negative high-dose 131I posttreatment whole body scans. van Tol KM; Jager PL; Dullaart RP; Links TP J Clin Endocrinol Metab; 2000 May; 85(5):2082-3. PubMed ID: 10843201 [No Abstract] [Full Text] [Related]
12. Role of PET scan in management of oesophageal cancer. Pramesh CS; Mistry RC Eur J Surg Oncol; 2005 May; 31(4):449. PubMed ID: 15837055 [No Abstract] [Full Text] [Related]
13. [Positron emission tomography-computed tomography with (18)F-fluorodeoxyglucose in patients with recurrent differentiated thyroid carcinoma and negative radioiodine scan. Diagnostic performance and relation with tyroglobulin levels]. Mariscal Labrador E; García Burillo A; Castell-Conesa J; Obiols Alfonso G; Kisiel González N; Barios Profitós M; Aguadé-Bruix S; Mesa Manteca J Rev Esp Med Nucl Imagen Mol; 2013; 32(3):146-51. PubMed ID: 22726673 [TBL] [Abstract][Full Text] [Related]
14. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation. Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522 [TBL] [Abstract][Full Text] [Related]
15. F-18 FDG PET/CT in the management of thyroid cancer. Iagaru A; Kalinyak JE; McDougall IR Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020 [TBL] [Abstract][Full Text] [Related]
16. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in cancer of the thyroid]. Bourguet P; Bull Cancer; 2003 Feb; 90 Spec No():S105-9. PubMed ID: 12739343 [No Abstract] [Full Text] [Related]
17. A new look at breast cancer. Wagner HN J Nucl Med; 1999 Jun; 40(6):1009-10. PubMed ID: 10452319 [No Abstract] [Full Text] [Related]